Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema
Purpose. Diabetic macular edema (DME) is a vision-threatening condition that develops in diabetic patients. The first-line therapy for DME is intravitreal injections of antivascular endothelial growth factor (anti-VEGF) agents; however, the high frequency of repeat injections, invasiveness of the pr...
Saved in:
| Main Authors: | Yoko Takatsuna, Ryoichi Ishibashi, Tomoaki Tatsumi, Masaya Koshizaka, Takayuki Baba, Shuichi Yamamoto, Koutaro Yokote |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Ophthalmological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2020/8867079 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparisons of One to Three Monthly Injections of Aflibercept for Diabetic Macular Edema by Practical Protocol
by: Yuko Hayashi, et al.
Published: (2021-01-01) -
Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents
by: E. R. Radkevich, et al.
Published: (2025-05-01) -
Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Kidney Disease and beyond
by: Zein Alabdin Hannouneh, et al.
Published: (2025-01-01) -
Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction
by: Nicia I. Profili, et al.
Published: (2025-03-01) -
Antifibrotic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure
by: Yu. S. Ignatova, et al.
Published: (2024-02-01)